Antitargets and Drug Safety

#01 Analysis of marketed drugs: The utility of AERS for early drug discovery/pitfalls
#02 In silico prediction of drug side effects
#03 Translational value of preclinical safety assessment: System organ class (SOC) representation of off-targets
#04 Pathological conditions associated with the disturbance of 5HT receptors
#05 Drug-induced Liver Injury ? Clinical and Diagnostic Aspects
#06 Mechanistic Safety Biomarkers for Drug-Induced Liver Injury
#07 In vitro models for the Prediction of Drug-Induced Liver Injury in Lead Discovery
#08 Transporters in the liver
#09 Mechanistic Modeling of Drug-Induced Liver Injury (DILI)
#10 Functional Cardiac Safety Evaluation of Novel Therapeutics
#11 Cav1.2
#12 Cardiac Sodium Current (Nav1.5)
#13 Circulating biomarkers for cardiotoxicity: reverse translation from human to preclinical species
#14 The Mechanistic Basis of hERG Blockade and the Proarrhythmic Effects Thereof
#15 Introduction to Kinase Anti-Targets
#16 Clinical and Nonclinical Adverse Effects of Kinase Inhibitors
#17 Cardiotoxicity of Kinase inhibitors
#18 Case Studies: Selective Inhibitors of Protein Kinases; Exploiting Demure Features
#19 Torcetrapib and Dalcetrapib Safety: Relevance of Preclinical In-Vitro and In-Vivo Models
#20 Targets associated with drug-related suicidal ideation and behavior

Laszlo Urban received his MD and PhD in neurophysiology/neuropharmacology in Hungary, and was visiting professor at Duke University between 1987 and 1989. He is currently global head of Preclinical Safety Profiling at the Novartis Institutes for Biomedical Research, Cambridge, USA, and was previously the Deputy Head of the Novartis Institute for Medical Sciences in London, UK. Dr. Urban has over 130 scientific articles, book chapters and patents to his name.
 
Roy J. Vaz received his PhD in organic chemistry from the University of Florida, Gainesville, an MBA from the University of Illinois, and most recently an MS in molecular biology from Lehigh University, USA. He is currently a senior distinguished scientist at Sanofi Pharmaceuticals in Waltham, MA, and was previously Director of the Investigative Product Optimization department under Aventis. He has worked at Bristol-Myers Squibb as Principal Scientist as well as at Tripos, Inc, as a research scientist. Dr. Vaz has authored or co-authored around 45 publications in peer-reviewed journals, eight book chapters and several patents.
 
Vinod Patel gained his BSc in applied chemistry from Leicester Polytechnic, and a PhD in synthetic organic chemistry from Nottingham University, UK. He took up a post-doctoral fellowship at the University of Rochester, NY, USA, before joining Eli Lilly & Company, where he spent the next nine years as a medicinal chemist in the oncology division. He then joined Kinetix Pharmaceuticals, which was acquired by Amgen and Dr. Patel joined their new Cambridge facility as head of medicinal chemistry. In 2011, he joined Sanofi oncology research as head of medicinal chemistry where he is currently head of chemical research in lead generation candidate realization. Dr. Patel has over 50 publications and some 50 patents to his name.